Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where A. Palmer is active.

Publication


Featured researches published by A. Palmer.


American Journal of Transplantation | 2006

Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity.

Richard Borrows; G. Chusney; M. Loucaidou; A. James; J. Lee; Jen Van Tromp; J. Owen; Thomas Cairns; M. Griffith; Nadey S. Hakim; A. McLean; A. Palmer; V. Papalois; David Taube

Studies of renal transplantation utilizing trough plasma level monitoring of mycophenolic acid (MPA) have shown inconsistent associations with toxicity and rejection.


American Journal of Transplantation | 2004

Steroid Sparing with Tacrolimus and Mycophenolate Mofetil in Renal Transplantation

Richard Borrows; Marina Loucaidou; Jen Van Tromp; Tom Cairns; M. Griffith; Nadey S. Hakim; A. McLean; A. Palmer; V. Papalois; David Taube

Evidence suggests that steroid sparing in renal transplantation is associated with good outcomes, although there are limited data regarding steroid sparing in Tacrolimus and Mycophenolate Mofetil (MMF)‐based regimes. In this study we describe the use of these agents in 101 consecutive patients undergoing renal transplantation using only a 7‐day course of prednisolone.


Nephron Clinical Practice | 2004

Prolonged Treatment with Low-Dose Intravenous Pulse Cyclophosphamide May Reduce Rate of Relapse in ANCA-Associated Vasculitis

Ajay Dhaygude; M. Griffith; Thomas Cairns; A. McLean; A. Palmer; David Taube

Background: Cyclophosphamide has transformed the outcome of ANCA-associated vasculitis, but it is highly toxic. Recent studies have suggested that pulsed intravenous cyclophosphamide (pCyc) is an effective alternative with less complications, but may lead to an increased rate of relapse. However, these studies used relatively short courses of treatment with cyclophosphamide. In this study we used a prolonged course of low-dose intravenous cyclophosphamide for 18–24 months for ANCA-associated vasculitis, evaluated the effectiveness of pCyc and analysed the outcome of a prolonged treatment on the rate of relapse. Methods: A retrospective analysis of all the patients treated with pCyc from 1995 to 2002 was performed. Results: Thirty-seven patients were followed for an average of 38 months. Thirty-four of 37 patients (91.9%) achieved complete remission at 3 months. Eight (21%) episodes of relapse occurred in 7 patients. The cyclophosphamide was well tolerated with a low rate of infections (18.9%) and 1 death (2.7%) due to sepsis whilst on cyclophosphamide. Conclusion: In this study, pCyc was effective in achieving rapid remission and had a low complication rate. If prolonged, this treatment may reduce the rate of relapse.


Nephrology Dialysis Transplantation | 2004

Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy

Neill Duncan; Ajay Dhaygude; Jane Owen; Thomas Cairns; M. Griffith; A. McLean; A. Palmer; David Taube


Transplantation Proceedings | 2005

Cytokine Polymorphisms Do Not Influence Acute Rejection in Renal Transplantation Under Tacrolimus-Based Immunosuppression

M. Loucaidou; J. Stitchbury; J. Lee; R. Borrows; Sara E. Marshall; A. McLean; Thomas Cairns; M. Griffith; Nadey S. Hakim; A. Palmer; V. Papalois; K. Welsh; David Taube


Transplantation Proceedings | 2001

Treatment of calcineurin inhibitor toxicity by dose reduction plus introduction of mycophenolate mofetil.

W McKane; C Kanganas; R Preston; T Cairns; Nadey S. Hakim; A. Palmer; David Taube


Transplantation Proceedings | 2005

Tacrolimus monitoring in renal transplantation : A comparison between high-performance liquid chromatography and immunoassay

R. Borrows; G. Chusney; M. Loucaidou; S. Singh; A. James; Jose Stichbury; J. Van Tromp; Thomas Cairns; M. Griffith; Nadey S. Hakim; A. McLean; A. Palmer; V. Papalois; David Taube


Transplantation Proceedings | 2001

Intra-arterial stenting for recurrent transplant renal artery stenosis.

S Fluck; R Preston; W McKane; A Harris; R Morgan; Wladyslaw Gedroyc; T Cairns; A. Palmer; David Taube


Transplantation Proceedings | 2005

Late Steroid Withdrawal for Renal Transplant Recipients on Tacrolimus and MMF Is Safe

M. Loucaidou; R. Borrows; Thomas Cairns; M. Griffith; Nadey S. Hakim; A. Palmer; V. Papalois; David Taube; A. McLean


Transplant International | 2001

European randomised trial of dual versus triple tacrolimus-based regimens for control of acute rejection in renal allograft recipients.

René W. S. Chang; Susan Snowden; A. Palmer; Jonathan T. C. Kwan; Michael L. Nicholson; S. Habib Kashi; Ossie N. Fernando; Ferenc Perner; Guy H. Neild

Collaboration


Dive into the A. Palmer's collaboration.

Top Co-Authors

Avatar

David Taube

Imperial College Healthcare

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge